Connecting the dots to the Future of Life Sciences Industry
THE INDUSTRY CONNECT
The Asia-Pacific biotechnology industry has been witnessing a growth phase on the back of several factors, such as cost effective manufacturing capabilities, improved clinical capabilities, growing health needs of large population base, exports and increasing government support among others. According to an industry report, the industry grew at the CAGR of 6.7 per cent between the years 2010-2014 to reach a total of USD77 billion in 2014. India is witnessing a new era of growth and opportunities in the Life Sciences/Healthcare sectors
With increasing pressure to reduce drug development costs and accelerate R&D programs, the global companies have started setting up R&D centers in Asia to take advantage of cost-effective, yet highly skilled talent pool. India has emerged as a preferred destination for contract research and manufacturing activities, process reengineering and innovative R&D to act as a single destination with various enablers in place. The country is aided by a large, highly skilled community of scientists and researchers. Additionally, the government’s support in bringing a comprehensive IPRPolicy, launch of ‘Make in India’ and financial support programs, regulatory reforms, etc. are expected to further boost the growth for Life Sciences industry.
THEME FOR BIOASIA 2016
Under this backdrop, the thirteenth edition of BioAsia will be organized from February 8-10, 2016 at Hyderabad International Convention Centre, with the theme of Leveraging India to succeed globally and shall focus on connecting the dots to build stakeholder consensus and draw a distinct road-map to propel the sector growth. Given the enormous potentials and promise offered by the sector, the event will bring together the global thought leaders, pharma & biotech companies, diagnostic companies, technology companies, medical practitioners, CROs, entrepreneurs and investors to enable cross pollination of ideas. The 13th BioAsia will be organized by Federation of Asian Biotech Associations, Government of Telangana and the Pharmaceutical Export Promotion Council of India in partnership with the Government of India & ‘Make in India’, with the objective of positioning India as the global life sciences & healthcare hub.
WHAT BIOASIA BRINGS TO THE TABLE
Over the years, BioAsia has come to represent the flagship event of domestic and international Life Sciences sector and has truly evolved in to a global platform witnessing participation of senior leaders from over 50 Countries. The success of BioAsia is largely attributed to the strong support and participation of industries which is witnessed in each edition. Given the demonstrated success over the years in terms of investments, business partnering and quality of the deliberations, Government of India (through Department of Biotechnology and Department of Pharmaceuticals) is playing a very active role in the planning and execution of the 13th BioAsia. In addition to the core biotech and pharma focus, the event will also collaborate with healthcare leaders, technology companies and entrepreneur community aimed at connecting the cross sectorial stakeholders to enable cross pollination of ideas. BioAsia 2016 will not just be bigger and better in terms of number of participants and scale, but will enable more meaningful dialogue between the stakeholders
FOCUS AREAS & ACTION PACKED CONFERENCES
The technology conferences at BioAsia 2016 are designed to be a Science-Business bridge that brings together a trans-disciplinary environment for driving innovation in the life sciences industry. While presenting an opportunity to explore partnerships and channels for extending business between industry and academia, BioAsia’s tech conferences will cover contemporary developments in research and will assist in building capabilities to break the barriers for smooth flow of technology and collaborations. The aim is to build a trans-disciplinary environment for driving innovation in the life sciences industry.
- Drug Discovery and Innovation Conference – Research & Development (R&D) activities, in particular, drug discovery require concentrated efforts at various levels, multiple skills and expertise. The global drug discovery industry is facing considerable challenges due to increasing costs, decreasing productivity, funding pressures and attrition of projects as they progress through the development process. Companies and health organizations across the world are responding with extensive re-organization, restructuring and re-focusing in order to address the issues around R&D productivity, process inefficiency, project attrition and the increasing costs of taking a potential new drug to the market and to secure profits. The Drug Discovery and Innovation conference at BioAsia 2016 will not only provide a common platform to create a roadmap for innovation but also propel the growth of drug discovery in India.
- Clinical Research Conference – Once considered a global clinical trial hub, India has been facing a lot of challenges with the Clinical Trial Conduct, Approval and Regulation. Despite the many hurdles, the Indian clinical trial industry has a promising future with the introduction of new regulations that will bring in greater transparency and clarity and India is poised to regain its position as the preferred destination to conduct Clinical Trials. Moving forward from the discussions during the 12th BioAsia Clinical Research Conference, it is indispensable to address issues and challenges that remain pertaining to Clinical Research in India and how it is being perceived worldwide. The conference will discuss the challenges and solutions for conducting clinical trials, the need-gap in the industry for clinical research in India and also share insights on the best practices from across the globe.
- Digital Health & Healthcare IT Conference – Despite the advantages of using advanced technology systems; greater technology adoption still faces its share of challenges. Currently, the IT budget for Indian hospitals does not exceed 10% of their revenues, which is substantially lower than what is allocated globally. Moreover, despite the long-term gains in efficiencies and costs that could be achieved, the initial high capital investments are likely to discourage organizations from considering investing in advanced technology systems presently. In addition to this, lack of in-house IT expertise, lack of quality standards, reluctance/resistance of the staff, inadequate support from the IT partners etc. are some of the bottlenecks that need the industry’s attention. The Digital Health & Healthcare IT Conference at BioAsia 2016 is expected to bring together the Life Sciences companies, healthcare players, IT companies and policy makers among other stakeholders to deliberate on various models that can seamlessly integrate technology and digitization in healthcare and Life Sciences.
BioAsia 2016 will provide a larger impetus to the healthcare and life sciences industry with conference themes, the ones above mentioned and many more; derived from the current industry trends and conceptualized to create many more opportunities than its previous editions.
BIOASIA 2016 - BIGGER AND BETTER!
Since its inception, BioAsia has been committed to fulfilling its core objective of serving as a global conclave to facilitate business in the pharmaceuticals, healthcare, life sciences sectors in India. Today, it is widely accepted as a catalyst for the life sciences industry since it provides a critical platform for B2B meetings helps in speedy resolution of key issues that affect the industry and sets the overall agenda. Over 200 bilateral cooperation agreements and MOUs have been signed through BioAsia. The conference has enabled bringing in trade & investments to an estimated extent of INR 13,736 Cr / ~USD 2.3 Billion. More than 20 knowledge papers have been released post the success of the past editions and more than 11,700 B2B, B2R and R2R meetings have realized.
Continuing its role as catalyst for the Indian life sciences industry, the 13th edition will be bigger and better with major breakthroughs in the form of a Partnership with the ‘Make in India’ initiative of the Government of India. BioAsia 2016, in conjunction with the ‘Make in India’ initiative will also host a Digital Health Start-Up pavilion to promote and showcase India’s vibrant start up community in emerging areas of healthcare, to the global leaders and investors.
Overall BioAsia 2016 provides tremendous opportunities for all sections Industry. BioAsia has truly evolved to become the right platform for industries and academia to discuss and understand the current trends of life sciences industry globally. We hope that the participants will take-away new perspectives/ insights from industry leaders, experts discussing the worlds’ best practices at the forum, while being able to connect with partnership / collaborative prospects at the event.
For more information
Phone: +91 (40) 3000 4005/4006